253 related articles for article (PubMed ID: 28771630)
1. Absence of microRNA-21 does not reduce muscular dystrophy in mouse models of LAMA2-CMD.
Moreira Soares Oliveira B; Durbeej M; Holmberg J
PLoS One; 2017; 12(8):e0181950. PubMed ID: 28771630
[TBL] [Abstract][Full Text] [Related]
2. Bortezomib Does Not Reduce Muscular Dystrophy in the dy2J/dy2J Mouse Model of Laminin α2 Chain-Deficient Muscular Dystrophy.
Körner Z; Durbeej M
PLoS One; 2016; 11(1):e0146471. PubMed ID: 26731667
[TBL] [Abstract][Full Text] [Related]
3. Increased polyamines as protective disease modifiers in congenital muscular dystrophy.
Kemaladewi DU; Benjamin JS; Hyatt E; Ivakine EA; Cohn RD
Hum Mol Genet; 2018 Jun; 27(11):1905-1912. PubMed ID: 29566247
[TBL] [Abstract][Full Text] [Related]
4. Natural disease history of the dy2J mouse model of laminin α2 (merosin)-deficient congenital muscular dystrophy.
Pasteuning-Vuhman S; Putker K; Tanganyika-de Winter CL; Boertje-van der Meulen JW; van Vliet L; Overzier M; Plomp JJ; Aartsma-Rus A; van Putten M
PLoS One; 2018; 13(5):e0197388. PubMed ID: 29763467
[TBL] [Abstract][Full Text] [Related]
5. Pax7, Pax3 and Mamstr genes are involved in skeletal muscle impaired regeneration of dy2J/dy2J mouse model of Lama2-CMD.
Yanay N; Elbaz M; Konikov-Rozenman J; Elgavish S; Nevo Y; Fellig Y; Rabie M; Mitrani-Rosenbaum S; Nevo Y
Hum Mol Genet; 2019 Oct; 28(20):3369-3390. PubMed ID: 31348492
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib partially improves laminin α2 chain-deficient muscular dystrophy.
Körner Z; Fontes-Oliveira CC; Holmberg J; Carmignac V; Durbeej M
Am J Pathol; 2014 May; 184(5):1518-28. PubMed ID: 24631023
[TBL] [Abstract][Full Text] [Related]
7. Laminin α1 reduces muscular dystrophy in dy
Gawlik KI; Harandi VM; Cheong RY; Petersén Å; Durbeej M
Matrix Biol; 2018 Sep; 70():36-49. PubMed ID: 29544677
[TBL] [Abstract][Full Text] [Related]
8. Effects of metformin on congenital muscular dystrophy type 1A disease progression in mice: a gender impact study.
Fontes-Oliveira CC; M Soares Oliveira B; Körner Z; M Harandi V; Durbeej M
Sci Rep; 2018 Nov; 8(1):16302. PubMed ID: 30389963
[TBL] [Abstract][Full Text] [Related]
9. A single point mutation in the LN domain of LAMA2 causes muscular dystrophy and peripheral amyelination.
Patton BL; Wang B; Tarumi YS; Seburn KL; Burgess RW
J Cell Sci; 2008 May; 121(Pt 10):1593-604. PubMed ID: 18430779
[TBL] [Abstract][Full Text] [Related]
10. Chimeric protein repair of laminin polymerization ameliorates muscular dystrophy phenotype.
McKee KK; Crosson SC; Meinen S; Reinhard JR; Rüegg MA; Yurchenco PD
J Clin Invest; 2017 Mar; 127(3):1075-1089. PubMed ID: 28218617
[TBL] [Abstract][Full Text] [Related]
11. Vemurafenib improves muscle histopathology in a mouse model of LAMA2-related congenital muscular dystrophy.
Oliveira-Santos A; Dagda M; Wittmann J; Smalley R; Burkin DJ
Dis Model Mech; 2023 Jun; 16(6):. PubMed ID: 37021539
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic laryngeal muscles are spared from degeneration in the dy3K/dy3K mouse model of congenital muscular dystrophy type 1A.
Häger M; Durbeej M
Muscle Nerve; 2009 Jan; 39(1):91-4. PubMed ID: 19086066
[TBL] [Abstract][Full Text] [Related]
13. Human laminin-111 and laminin-211 protein therapy prevents muscle disease progression in an immunodeficient mouse model of LAMA2-CMD.
Barraza-Flores P; Hermann HJ; Bates CR; Allen TG; Grunert TT; Burkin DJ
Skelet Muscle; 2020 Jun; 10(1):18. PubMed ID: 32498713
[TBL] [Abstract][Full Text] [Related]
14.
Christen M; Indzhova V; Guo LT; Jagannathan V; Leeb T; Shelton GD; Brocal J
Genes (Basel); 2021 Nov; 12(11):. PubMed ID: 34828429
[TBL] [Abstract][Full Text] [Related]
15. Antioxidants Reduce Muscular Dystrophy in the
Harandi VM; Oliveira BMS; Allamand V; Friberg A; Fontes-Oliveira CC; Durbeej M
Antioxidants (Basel); 2020 Mar; 9(3):. PubMed ID: 32197453
[TBL] [Abstract][Full Text] [Related]
16. Electrophysiology of the neuromuscular junction of the laminin-2 (merosin) deficient C57 BL/6J dy2J/dy2J dystrophic mouse.
Edwards JP; Hatton PA; Wareham AC
Brain Res; 1998 Mar; 788(1-2):262-8. PubMed ID: 9555049
[TBL] [Abstract][Full Text] [Related]
17. Current understanding and treatment of cardiac and skeletal muscle pathology in laminin-α2 chain-deficient congenital muscular dystrophy.
Nguyen Q; Lim KRQ; Yokota T
Appl Clin Genet; 2019; 12():113-130. PubMed ID: 31308722
[TBL] [Abstract][Full Text] [Related]
18. Laminin alpha2 chain-null mutant mice by targeted disruption of the Lama2 gene: a new model of merosin (laminin 2)-deficient congenital muscular dystrophy.
Miyagoe Y; Hanaoka K; Nonaka I; Hayasaka M; Nabeshima Y; Arahata K; Nabeshima Y; Takeda S
FEBS Lett; 1997 Sep; 415(1):33-9. PubMed ID: 9326364
[TBL] [Abstract][Full Text] [Related]
19. Laminin-111 protein therapy after disease onset slows muscle disease in a mouse model of laminin-α2 related congenital muscular dystrophy.
Barraza-Flores P; Bukovec KE; Dagda M; Conner BW; Oliveira-Santos A; Grange RW; Burkin DJ
Hum Mol Genet; 2020 Aug; 29(13):2162-2170. PubMed ID: 32472139
[TBL] [Abstract][Full Text] [Related]
20. LAMA2-related myopathy: Frequency among congenital and limb-girdle muscular dystrophies.
Løkken N; Born AP; Duno M; Vissing J
Muscle Nerve; 2015 Oct; 52(4):547-53. PubMed ID: 25663498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
